SG Americas Securities
CRSP icon

SG Americas Securities’s CRISPR Therapeutics CRSP Stock Holding History

SG Americas Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200,000
Closed -$1.88M – 3447
2021
Q3 		$1.88M Buy
+200,000
New +$25.1M 0.01% 1325

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SG Americas Securities's CRSP Position: Q1 2026 in Review

SG Americas Securities reduced its CRISPR Therapeutics (CRSP) stake by 73% in Q1 2026, selling an estimated $533K and leaving 3,737 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

SG Americas Securities first reported a position in CRSP in Q3 2019 and has held it in 26 quarters since. The position peaked at $9.83M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • SG Americas Securities held 3,737 shares of CRISPR Therapeutics worth $178K as of Q1 2026.
  • SG Americas Securities sold 10,097 CRISPR Therapeutics shares in Q1 2026, an estimated $533K.
  • CRISPR Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2699 holding.
  • SG Americas Securities first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • SG Americas Securities's CRISPR Therapeutics position peaked at $9.83M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.